Den Europæiske Union - dansk - EMA (European Medicines Agency)

infai, institut für biomedizinische analytik nmr-imaging gmbh - urea (13c) - breath tests; helicobacter infections - diagnostiske midler - helicobacter test infai kan anvendes til in vivo-diagnosticering af gastroduodenal helicobacter pylori-infektion i:voksne, unge, der er tilbøjelige til at have mavesår sygdom. helicobacter test infai til børn i alderen tre til 11 år kan anvendes til in vivo-diagnosticering af gastrduodenal helicobacter pylori infektion:til evaluering af succes af udryddelse behandling, eller når invasive tests ikke kan udføres, eller, når der er diskordante resultater fra de invasive tests. dette lægemiddel er kun til diagnostisk brug.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

the simple pharma company limited - testosteron - transdermal gel - 20 mg/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - testosteron - transdermal gel - 20 mg/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - testosteron - transdermal gel - 20 mg/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

epione medicine aps - testosteron - transdermal gel - 20 mg/g

Den Europæiske Union - dansk - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinale stromale tumorer - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - imatinib - precursor cell lymphoblastic leukemia-lymphoma; gastrointestinal stromal tumors; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - antineoplastiske midler - glivec is indicated for the treatment of , adult and paediatric patients with newly diagnosed philadelphia-chromosome (bcr-abl)-positive (ph+) chronic myeloid leukaemia (cml) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed philadelphia-chromosome-positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (mds / mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and / or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfra rearrangement. virkningen af glivec om resultatet af knogle-marrow transplantation er ikke fastlagt. glivec is indicated for: , the treatment of adult patients with kit (cd 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (gist);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patienter, der har en lav eller meget lav risiko for tilbagefald, bør ikke modtage adjuverende behandling, behandling af voksne patienter med inoperabel dermatofibrosarcoma protuberans (dfsp) og voksne patienter med tilbagevendende og / eller metastatisk dfsp, som ikke er berettiget til kirurgi. i voksne og pædiatriske patienter, virkningen af glivec er baseret på det samlede hæmatologiske og cytogenetisk respons priser og progression-fri overlevelse i cml, på hæmatologiske og cytogenetisk respons priser i ph+ all, mds / mpd, på hæmatologiske svarprocenten i hes / cel og på objektive responsrater i voksne patienter med inoperabel og / eller metastatisk gist og dfsp og på recidiv-fri overlevelse i adjuvans kernen. erfaringerne med glivec hos patienter med mds / mpd, der er forbundet med pdgfr gen re-arrangementer er meget begrænset (se afsnit 5. undtagen i nyligt diagnosticeret kronisk cml-fase, der er ingen kontrollerede undersøgelser, der påviser en klinisk fordel eller øget overlevelse for disse sygdomme.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

smartpractice denmark aps - alfa-amylcinnamaldehyd, almindelig slåenlav (evernia prunastri), benzocain, benzylparahydroxybenzoat, butylparahydroxybenzoat, chlorquinaldol, cinchocainhydrochlorid, cinnamaldehyd, cinnamylalkohol, clioquinol, cyclohexylbenzothiazylsulfenamid, dibenzothiazyldisulfid, dipentamethylenthiuramdisulfid, diphenylguanidin, disulfiram, epoxyresin, ethylendiamindihydrochlorid, ethylparahydroxybenzoat, eugenol, geraniol, hydroxycitronellal, isoeugenol, kaliumdichromat, koboltchlorid, kolofonium, lanolinalkohol, merc - plaster til provokationstest

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

smartpractice denmark aps - alfa-amylcinnamaldehyd, almindelig slåenlav (evernia prunastri), benzocain, benzylparahydroxybenzoat, butylparahydroxybenzoat, chlorquinaldol, cinchocainhydrochlorid, cinnamaldehyd, cinnamylalkohol, clioquinol, cyclohexylbenzothiazylsulfenamid, dibenzothiazyldisulfid, dipentamethylenthiuramdisulfid, diphenylguanidin, disulfiram, epoxyresin, ethylendiamindihydrochlorid, ethylparahydroxybenzoat, eugenol, geraniol, hydroxycitronellal, isoeugenol, kaliumdichromat, koboltchlorid, kolofonium, lanolinalkohol, mercaptobenzothiazol, methylchlorisothiazolinon, methylparahydroxybenzoat, morpholinylmercaptobenzothiazol, n-cyclohexyl-n-phenylparaphenylendiamin, n-hydroxymethylsuccinimid, n-isopropyl-n-phenylparaphenylendiamin, n,n-diphenylparaphenylendiamin, neomycinsulfat, nikkelsulfat, p-tert butylphenol formaldehyd harpiks, paraphenylendiamin, perubalsam, propylparahydroxybenzoat, quaternium-15, tetracainhydrochlorid, tetramethylthiurammonosulfid, thiomersal, thiram, zinkdibutyldithiocarbamat, zinkdiethyldithiocarbamat - plaster til provokationstest